Macdougall Iain C, Eckardt Kai-Uwe
Department of Renal Medicine, King's College Hospital, London SE5 9RS, UK.
Lancet. 2006 Sep 9;368(9539):947-53. doi: 10.1016/S0140-6736(06)69120-4.
As with many other therapeutic areas in modern-day medicine, scientific advances in drug development (using such techniques as recombinant DNA technology, site-directed mutagenesis, pegylation of molecules, peptide library screening, and gene transfer) have resulted in the development of potential new agents and strategies for stimulating erythropoiesis. These advances are of possible benefit in treating anaemia due to various causes, including chronic renal failure. Several new treatments will soon become clinically available, while others are at present at an early stage of development but are nevertheless of scientific interest. We review these new therapeutic strategies, and discuss at what stage some of the newer products are in relation to their clinical development programme.
与现代医学中的许多其他治疗领域一样,药物研发方面的科学进展(采用重组DNA技术、定点诱变、分子聚乙二醇化、肽库筛选和基因转移等技术)已促成了刺激红细胞生成的潜在新药物和新策略的开发。这些进展对于治疗包括慢性肾衰竭在内的各种病因引起的贫血可能有益。几种新疗法很快将可用于临床,而其他一些疗法目前尚处于早期开发阶段,但仍具有科学研究价值。我们将对这些新的治疗策略进行综述,并讨论一些较新产品在其临床开发计划中所处的阶段。